Earnings summaries and quarterly performance for GLAUKOS.
Executive leadership at GLAUKOS.
Board of directors at GLAUKOS.
Research analysts who have asked questions during GLAUKOS earnings calls.
AG
Allen Gong
JPMorgan Chase & Co.
4 questions for GKOS
Also covers: ESTA, INGN, IRTC +2 more
AP
Anthony Petrone
Mizuho Group
4 questions for GKOS
Also covers: ADMA, ALC, BSX +22 more
LB
Larry Biegelsen
Wells Fargo & Company
4 questions for GKOS
Also covers: ABT, ALC, AXNX +24 more
MS
Michael Sarcone
Jefferies
4 questions for GKOS
Also covers: ALC, AXGN, CTSO +11 more
Ryan Zimmerman
BTIG
4 questions for GKOS
Also covers: ALC, GEHC, GMED +23 more
Thomas Stephan
Stifel
4 questions for GKOS
Also covers: ALC, RXST, SGHT +1 more
DA
Danielle Antalffy
UBS Group AG
3 questions for GKOS
Also covers: ABT, ATRC, BAX +15 more
DS
David Saxon
Needham & Company
3 questions for GKOS
Also covers: ALC, ALGN, ATEC +11 more
Joanne Wuensch
Citigroup Inc.
3 questions for GKOS
Also covers: ABT, BAX, BDX +18 more
RN
Richard Newitter
Truist Securities
3 questions for GKOS
Also covers: AXNX, DXCM, GMED +18 more
Adam Maeder
Piper Sandler Companies
2 questions for GKOS
Also covers: ABT, AXNX, EW +13 more
MC
Mason Carrico
Stephens Inc.
2 questions for GKOS
Also covers: AKYA, CDNA, CSTL +13 more
Patrick Wood
Morgan Stanley
2 questions for GKOS
Also covers: ALC, BDX, BLCO +17 more
SL
Steven Lichtman
Oppenheimer & Co. Inc.
2 questions for GKOS
Also covers: ALC, ANGO, COO +12 more
KG
K. Gong
JPMorgan Chase & Co.
1 question for GKOS
Also covers: ESTA
MK
Macauley Kilbane
William Blair & Company
1 question for GKOS
Also covers: CBLL, CVRX, IRTC +4 more
MO
Matthew O'Brien
Piper Sandler & Co.
1 question for GKOS
Also covers: APYX, ATEC, ATRC +18 more
RM
Ravi Misra
Truist Securities
1 question for GKOS
Also covers: IART, TFX
Recent press releases and 8-K filings for GKOS.
Glaukos Corporation Updates on Product Pipeline, Market Strategy, and Financials
GKOS
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Glaukos has invested $800 million in R&D since 2018, resulting in 12 commercially available products and 13 in development, and has achieved over 20% CAGR every year for 10 years with over 30% market growth in the past year. The company maintains an 84% gross margin profile and a healthy balance sheet of $283 million.
- The company is focused on transforming glaucoma and keratoconus treatment paradigms. For glaucoma, the iDose TR product demonstrated 81% of patients off all medications at one year in Phase III trials , and the next-generation iDose TREX, currently in Phase II-B/III clinical trials, is expected to last six years with a single injection.
- For keratoconus, Epioxa, a new topical drug that arrests sight-threatening disease, has met FDA requirements and is anticipated to replace Photrexa, with a manageable reimbursement process expected.
- In the most recent quarter, Glaukos reported $45 million in iDose revenue, reflecting good sequential growth despite a deceleration from prior quarters. The company is also encouraged by recent constructive dialogue with the FDA regarding the PDUFA date for iDose readministration.
7 days ago
GKOS Highlights Innovation, Product Pipeline, and Market Strategy at J.P. Morgan Healthcare Conference
GKOS
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- GKOS has invested $800 million in R&D since 2018, yielding 12 commercially available products and 13 in various phases of development, contributing to over 30% market growth in the most recent quarter and a 20% CAGR over the past 10 years.
- The company is focused on transforming glaucoma treatment with iDose TR, which demonstrated 81% of patients off all medications at one year in Phase 3 trials, and is developing next-generation products like iDose TREX, targeting six years of therapy.
- GKOS is launching Epioxa for keratoconus, strategically discontinuing Photrexa, and anticipates a "hand-to-hand combat" approach for reimbursement with commercial payers, a process different from iDose.
- The company is exiting the year with iDose on a $180-$190 million run rate and aims for continued model leverage and cash flow break-even in the midterm, while reinvesting in its pipeline and the Epioxa launch.
7 days ago
Glaukos Corporation Discusses Innovation Strategy and Product Pipeline at J.P. Morgan Healthcare Conference
GKOS
Product Launch
New Projects/Investments
Guidance Update
- Glaukos emphasizes its innovation-driven strategy, having invested $800 million in R&D since 2018, leading to 12 commercial products and 13 in development, and has achieved over 20% CAGR for the past decade.
- The company is focused on two key areas: interventional glaucoma with products like iDose TR, which has demonstrated sustained efficacy and is awaiting a PDUFA date for repeat administration at the end of January 2026, and iStent Infinite, targeting an expanded claim by the end of 2027.
- Glaukos is also building a new market in interventional keratoconus with Epioxa, an oxygen-infused topical drug, with a J-code targeted for July 2027 to increase patient access.
- Financially, Glaukos expects continued leverage in 2026 and aims for midterm profitability, with a near-term focus on cash flow break-even and generation, while continuing significant investments in product launches and its pipeline.
7 days ago
Glaukos Announces Preliminary Q4 and Full Year 2025 Net Sales and Reaffirms 2026 Guidance
GKOS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Glaukos Corporation reported preliminary, unaudited net sales of $143 million for the fourth quarter of 2025, marking a 36% increase compared to the same period in 2024.
- For the full year 2025, preliminary, unaudited total net sales are expected to be $507 million, representing a 32% increase over full year 2024.
- The company reaffirmed its full year 2026 net sales guidance in the range of $600 million to $620 million.
- As of December 31, 2025, Glaukos maintained a strong financial position with approximately $283 million in cash and cash equivalents and no debt.
7 days ago
Glaukos Announces Preliminary Q4 and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
GKOS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Glaukos expects preliminary, unaudited net sales for Q4 2025 to be approximately $143 million, representing a 36% increase compared to the same period in 2024, and full year 2025 net sales to be approximately $507 million, a 32% increase compared to full year 2024.
- iDose TR net sales are anticipated to be approximately $45 million in Q4 2025 and $136 million for the full year 2025.
- The company ended Q4 2025 with approximately $283 million in cash and cash equivalents, short-term investments, and restricted cash, and no debt.
- Glaukos reaffirms its 2026 net sales guidance range of $600 million to $620 million.
7 days ago
Glaukos Highlights Strong Product Pipeline, Upcoming Epioxa Launch, and Robust Financials
GKOS
Product Launch
New Projects/Investments
- Glaukos is advancing its Interventional Glaucoma (IG) and Interventional Keratoconus (IK) portfolios, with iDose TR FDA-approved in 2023 for glaucoma and Epioxa FDA-approved in 2025 for keratoconus.
- The company plans the commercial launch of Epioxa in 1Q 2026, which is the first and only FDA-approved epithelium-on treatment for keratoconus.
- Glaukos maintains a robust product pipeline, including iDose TRIO in Phase 3b, iDose TREX in Phase 2b/3, and iStent infinite label expansion expected in 2025.
- The company reported a gross margin of 84% in 3Q 2025 and a healthy balance sheet with $283 million in cash and equivalents and no debt as of December 31, 2025.
Jan 12, 2026, 9:00 PM
Glaukos Discusses iDose Launch Progress, Epioxa Strategy, and Financial Outlook at Citi Conference
GKOS
Product Launch
Guidance Update
New Projects/Investments
- Glaukos is transitioning towards generating more pharmaceutical revenue than device revenue, driven by its pipeline and product strategy.
- The iDose launch is progressing, with four of seven Medicare Administrative Contractors (MACs), representing approximately 70% of Medicare lives, now having professional fee schedules for the product. The clinical performance of iDose continues to exceed expectations.
- The company has launched Epioxa, its first rare disease drug for keratoconus, and has built a dedicated organizational foundation for rare disease market access and patient support.
- Glaukos aims for cash flow break-even in the near term and projects operating margins of 30% to 35% in the medium to long term, supported by its high gross margins.
- The traditional MIGS stent business is expected to be "flattish" next year, partly due to iDose cannibalizing some of its growth.
Dec 3, 2025, 6:45 PM
Glaukos Discusses Strategic Shift to Pharmaceuticals, iDose Launch Progress, and Financial Outlook at Global Healthcare Conference
GKOS
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Glaukos is transitioning from a microtechnology stent manufacturer to a company with a growing focus on pharmaceutical revenue, highlighted by the recent launch of Epioxa, a rare disease drug for keratoconus.
- The launch of iDose in 2025 has demonstrated strong clinical performance, exceeding expectations, though it faces ongoing challenges with professional fee reimbursement from Medicare Administrative Contractors (MACs); currently, four of seven MACs cover professional fees, representing 70% of Medicare lives.
- The legacy stent and MIGS franchise is projected to be flattish next year, with concomitant MIGS reimbursement expected to decline by low double digits for 2026 on the professional fee side.
- Financially, Glaukos is working towards achieving cash flow break-even in the near term and anticipates reaching 30%-35% operating margins in a mature business.
- The company's pipeline includes a next-generation iDose (TREX) designed for longer duration and an in-office injector system (Trio), both currently undergoing clinical development.
Dec 3, 2025, 6:45 PM
Glaukos Discusses Strategic Shift, iDose Reimbursement, and Financial Outlook for FY 2025
GKOS
Product Launch
Guidance Update
New Projects/Investments
- Glaukos is undergoing a strategic shift, moving from primarily a microtechnology manufacturer of stents (MIGS) to a company with significant pharmaceutical revenue, notably from iDose and the newly launched Epioxa.
- The core MIGS market (excluding iDose) is anticipated to be flattish in FY 2025, partly due to iDose cannibalization. For iDose, four of seven MACs, covering approximately 70% of Medicare lives, currently have professional fee schedules, with the company continuing education efforts for the remaining three.
- Financially, Glaukos is targeting cash flow breakeven in the near term and expects to achieve 30%-35% operating margins in the medium to long term, supported by high gross margins and the retirement of convertible debt.
- The company is also developing iDose TREX, a next-generation iDose designed to deliver twice the drug payload for extended duration, with clinical studies underway.
Dec 3, 2025, 6:45 PM
Glaukos Reports Strong Q3 2025 Results and Provides 2026 Revenue Guidance
GKOS
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Glaukos reported record third-quarter 2025 revenue of $133.5 million, representing mid-to-high 30% growth, driven by U.S. glaucoma revenue of $81 million (57% year-over-year growth) primarily from iDose.
- The company achieved a gross margin of almost 84% and maintained a cash balance of $277.5 million. Gross margin is expected to continue increasing due to the growing mix of high-margin iDose and Epioxa products.
- Glaukos announced preliminary 2026 revenue guidance of $600 million to $620 million, supported by multiple revenue drivers including iDose and the upcoming launch of Epioxa.
- For the Epioxa launch, the product is priced at $78,500 per eye, with an expected net ASP of $65,000-$70,000. The company plans to discontinue Photrexa in a staged process throughout 2026, aiming to significantly increase the number of treated keratoconus patients beyond the current 10,000 annually.
- The core U.S. stent business (non-iDose) is anticipated to be flattish or grow in the low to mid-single digits in 2026, while the broader combo cataract market is expected to return to growth after anniversarying LCD headwinds.
Nov 18, 2025, 4:00 PM
Quarterly earnings call transcripts for GLAUKOS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more